Chronic Kidney Disease Patients
Conditions
Keywords
potassium losartan, CKD, nondipping BP pattern
Brief summary
Nondipping blood pressure (BP) pattern is a potential independent risk factor for chronic kidney disease (CKD). Whether bedtime administration of potassium losartan has benefit for anti-hypertension and the prognosis of CKD patients is not clear. Patients with nondipping BP pattern or dipping BP pattern were enrolled in this study, and the patients with nondipping BP pattern were randomly divided into two groups and treated with bedtime or awakening doses of potassium losartan.
Detailed description
Patients with nondipping BP pattern or dipping BP pattern were enrolled in this study, and the patients with nondipping BP pattern were randomly divided into two groups and treated with bedtime or awakening doses of potassium losartan. Any patients who had any antihypertension medication at bedtime would withdrawal the drugs for 2 weeks before ABPM. Patients with nondipping BP were then randomly divided into two groups and received a bedtime or awakening dose of potassium losartan. Patients with dipping BP were called the dipper group, while the patients with nondipping BP were called the awakening dose group or bedtime dose group, according to the time of drug administration.
Interventions
treated with bedtime or awakening doses of potassium losartan
Sponsors
Fifth Affiliated Hospital, Sun Yat-Sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* night BP is SBP≥120mmHg and/or DBP≥70mmHg； * presence of CKD; * estimated GFR (eGFR)\<90 mL⁄ min ⁄ 1.73 m2 (using the Modification of Diet in Renal Disease Study equation) but \>30 mL⁄ min ⁄1.73 m2; * signed informed consent from participating patients.
Exclusion criteria
* pregnancy; * tumor; * infection; * renal replacement; * history of drug or alcohol abuse; * night- or shift-work employment; * treatment with steroids or hormonal therapy; * acute changes in eGFR \>30% in the past 3 months; * presence of acquired immunodeficiency syndrome; * CV disorders (unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure,and grade III or IV retinopathy); * intolerance to ambulatory BP monitoring (ABPM); * inability to communicate and comply with all of the study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| renal events and Cardiovascular events | 5 years | doubled creatine or renal replacement, myocardial infarction, heart failure, stroke, vascular reconstruction, peripheral vascular disease, non-traumatic amputation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| proteinuria | 5 years | 24h proteinuria \>1g |
| renal function | 5 years | eGFR\<30ml/min/1.73m2 |
| Thickness of the medial membrane of the carotid artery | 5 years | cIMT \>1mm |
| Left ventricle weight index | 5 years | LVMI \>115g/m2 (man) 和 \>95g/m2 (woman) |
Countries
China
Contacts
Primary ContactCheng Wang, Doctor
Backup ContactYe Zhu, Doctor
Outcome results
None listed